drugset / Trial / NCT02471911
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Phase 1
Completed
22 enrolled
Weill Medical College of Cornell University
FDA Office of Orphan Products Development · collabKaryopharm Therapeutics Inc · collabThe Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
Timeline
- Start
- 2015-12-11
- Primary completion
- 2019-10-31
- Completion
- 2021-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 20 mg | Oral |
| Subject | Selinexor | Other / unclassified | 100 mg | Oral |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 5 g | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |